The Case for Investment
With 10 million new cases and 1.6 million deaths in 2017, TB is deadlier than HIV, malaria, or even Ebola. Yet TB vaccine research only receives a fraction of the investment put into other diseases (under $100M a year).
Advocating for Resources to Match the Scale of the Problem
TB research and development is significantly underfunded. Investments in TB vaccine R&D have averaged $95 million per year over 2011-2016, less than half of the $250 million per year needed to advance TB vaccines. Aeras advocates for an expanded and diversified funding base to help ensure long-term financial support for urgently needed TB vaccine research and development.
We know that new, effective vaccines are both essential to the fight against TB and ultimately achievable — but only with sustained global investment and support.